Show simple item record

dc.contributor.authorFlower, KJen_US
dc.contributor.authorGhaem-Maghami, Sen_US
dc.contributor.authorBrown, Ren_US
dc.coverage.spatialNetherlandsen_US
dc.date.accessioned2019-02-26T15:55:16Z
dc.date.issued2018en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/28176650en_US
dc.identifierCCDT-EPUB-81520en_US
dc.identifier.citationCurr Cancer Drug Targets, 2018, 18 (1), pp. 5 - 15en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3100
dc.identifier.eissn1873-5576en_US
dc.identifier.doi10.2174/1568009617666170206105131en_US
dc.description.abstractThe efficacy of cancer immunotherapy relies on the ability of the host immune system to recognise the cancer as non-self and eliminate it from the body. Whilst this is an extremely fertile area of medical research, with positive clinical trials showing durable responses, attention must be paid to the subset of patients that do not respond to these treatments. Immune surveillance and immunoediting by the host could itself select for immune-evasive tumour cells during tumour development leading to immunotherapy resistance. One such mechanism of non-efficacy or resistance is the epigenetic silencing of a specific gene required in the immunotherapy response pathway. Epigenetics is the study of the control of expression patterns in a cell via mechanisms not involving a change in DNA sequence. All tumour types show aberrant epigenetic regulation of genes involved in all the hallmarks of cancer, including immunomodulation. Inhibition of key enzymes involved in maintenance of epigenetic states is another important area of research for new treatment strategies for cancer. Could epigenetic therapies be used to successfully enhance the action of immunomodulatory agents in cancer, and are they acting in the way we imagine? An understanding of the effects of epigenetic therapies on immunological pathways in both the tumour and host cells, especially the tumour microenvironment, will be essential to further develop such combination approaches.en_US
dc.format.extent5 - 15en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectCancer immunotherapyen_US
dc.subjectchemotherapy.en_US
dc.subjectimmune-evasive tumour cellsen_US
dc.subjectimmunomodulatory agentsen_US
dc.subjectradiotherapyen_US
dc.subjecttumour microenvironmenten_US
dc.subjectAnimalsen_US
dc.subjectEpigenesis, Geneticen_US
dc.subjectHumansen_US
dc.subjectImmunologic Factorsen_US
dc.subjectImmunomodulationen_US
dc.subjectImmunotherapyen_US
dc.subjectNeoplasmsen_US
dc.subjectTumor Microenvironmenten_US
dc.titleIs there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?en_US
dc.typeJournal Article
dcterms.dateAccepted2016-09-30en_US
rioxxterms.versionofrecord10.2174/1568009617666170206105131en_US
rioxxterms.licenseref.startdate2018en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfCurr Cancer Drug Targetsen_US
pubs.issue1en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Medicine (Brown Epigenetic Therapy)
pubs.publication-statusPublisheden_US
pubs.volume18en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMedicine (Brown Epigenetic Therapy)en_US
dc.contributor.icrauthorBrown, Roberten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record